Arkady V. Nekrasov

Founder of NPO Petrovax Pharm, Professor, Doctor of Chemistry, Winner of Russian State Award

  • Petrovax Pharm is founded
  • Polyoxidonium® and Grippol® are registered
  • Prof. Arkady Nekrasov and his team are awarded the Russian Federation State Prize for Polyoxidonium® and Grippol® development and implementation in the country’s healthcare system.
  • A facility is launched to manufacture APIs, semi-solid and solid dosage forms (tablets) and injectables.
  • Partnership with Solvay Pharma (currently, Abbott).
Полиоксидоний - таблетки 12 мг - Вправо.jpgIn 2002 the development team headed by Professor A. Nekrasov was awarded the State Prize of the Russian Federation for creation and implementation of Polyoxidonium and Grippol in the healthcare practice.
  • Longidaze® is launched to the market.
  • A state-of-the-art GMP-compliant manufacturing and warehousing complex is put in operation in Pokrov (Podolsk District, Moscow Region).
  • Launch of a unique pre-filled syringe line.
  • Grippol® Pluspreservative-free innovative influenza vaccine is launched to the market.
  • Development and manufacturing of the A/H1N1 pandemic influenza vaccines MonoGrippol Neo, MonoGrippol Plus, and MonoGrippol.
  • The WHO approves Azoximer bromide as the INN for Polyoxidonium®.
  • Grippol® plus vaccine manufacturing for the National Immunization Schedule.
  • Partnership with Pfizer to localize production of a 13-valent pneumococcal conjugate vaccine (including vaccine manufacturing and registration). This project received a Russian Platinum Ounce award.
  • Polyoxidonium®Vet Solution is registered for veterinary use.
  • EU GMP audit successful completion.
  • NPO Petrovax Pharm controlling interest is acquired by Interros Group owner and founder Vladimir Potanin’s company.
  • Agreements are signed on Grippol Plus flu vaccine manufacturinglocalization in the Republic of Belarus and Iran.
  • Imoferaza®, an innovative special care cosmetic cream for post-trauma, post-surgical and post-acne scars is launched to the market.
  • The WHO approves bovhyaluronidase azoximer as the INN for Longidaze®.
  • The Russian Ministry of Health licenses Petrovax Pharm to manufacture Grippol® Plus, a Russian influenza vaccine, using flu antigens produced by St. Petersburg Research Institute for Vaccines and Sera of Russia’s Federal Medical and Biological Agency.
  • Partnership with Boehringer Ingelheim to localize a full-cycle manufacturing of the most advanced cardiovascular pharmaceutical products. The first commercial Metalyse® batches are produced.
  • Polyoxidonium® is a two-time winner of the Russian Pharma Awards (2016 and 2017). Polyoxidonium® tablets label is extended to include children aged 3+ years. A Post-Authorization Safety Study (PASS) for Polyoxidonium® is successfully completed in Europe (Slovakia).
  • Petrovax Pharm is announced the winner of the All-Russia Contest «Russian Business Leaders: Performance and Commitment’2017» in the category «For the Dynamic Development of Business».
  • Grippol® Quadrivalent registration dossier is submitted for review and approval.

Grippol Welson

  • Grippol® Quadrivalent, the first in Russia 4-valent influenza vaccine, launched to the market. NPO Petrovax Pharm won the National Import Substitution Award ‘PRIORITY-2018’ for Grippol® Quadrivalent vaccine. Petrovax has also expanded its product portfolio due to Velson® (melatonin) that provides for falling asleep faster and improves sleep quality.
  • NPO Petrovax Pharm manufacturing complex marked its 10-year anniversary; the 3rd production line for API, tablets, and suppositories presented. The company’s new production line has been licensed and certified to the Russian GMP standards. The conformity of the manufacturing processes and the Quality Management System (QMS) to the applicable EU GMP regulations (Slovakia) has been confirmed. The medicinal product labeling project has been implemented. The first batches of Polyoxidonium® labeled in accordance with the mandatory EU requirements have been supplied to Slovakia.
  • Petrovax Pharm’s products won the 7th Russian Pharma Awards contest: Polyoxidonium® - in the category ‘The Medication of Choice for ARVI and influenza prevention in children’; Longidaze® - in the category ‘The Medication of Choice for pathogenetic treatment of chronic prostatitis and relapse prevention’.
  • The company has been rebranded. The new corporate style reflects the new strategy aimed at product portfolio expansion and intensive international integration. The brand has retained its consistency and individual touch while having become simpler and more state-of-the-art.
1.png Petrovax

  • Large-scale clinical trials of original pharmaceutical products Polyoxidonium® and Longidaze® in the prevention and treatment of COVID-19.
  • Commissioning the second manufacturing facility for production of APIs, soft and solid dosage forms. The line made it possible to increase production of APIs (2.5x) times, suppositories (4x) and tablets (7x).
  • Implementation of the Russian-Chinese project on the development and subsequent production of Convidicea, a recombinant adenovirus-based viral vector vaccine for the prevention of COVID-19, in cooperation with CanSino Biologics Inc.
  • Launch of new products:
  • Uronext®, a complex remedy for urinary tract infections.
  • VitaFerr®, a complex product for prevention of iron deficiency among women.
  • Polyoxidonium® solution, a new dosage form.
  • Charitable assistance to the Podolsk City Clinical Hospital in equipping a new hospital against COVID-19. More than 20 thousand packages of Polyoxidonium® were donated to healthcare professionals working in the red zones for the prevention of COVID-19.

© Petrovax
The materials posted on the site are for informational purposes only and are not intended to advertise or promote the manufacturer or medications produced.